Detalles de la búsqueda
1.
Phase I dose-escalation and pharmacokinetic study of ispinesib, a kinesin spindle protein inhibitor, administered on days 1 and 15 of a 28-day schedule in patients with no prior treatment for advanced breast cancer.
Anticancer Drugs
; 23(3): 335-41, 2012 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-22123335
Resultados
1 -
1
de 1
1
Próxima >
>>